AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation

Martin J. Hicks, Jonathan B. Rosenberg, Bishnu P. De, Odelya E. Pagovich, Colin N. Young, Jian Ping Qiu, Stephen M. Kaminsky, Neil R. Hackett, Stefan Worgall, Kim D. Janda, Robin L. Davisson, Ronald Crystal

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Current strategies to help tobacco smokers quit have limited success as a result of the addictive properties of the nicotine in cigarette smoke. We hypothesized that a single administration of an adeno-associated virus (AAV) gene transfer vector expressing high levels of an anti-nicotine antibody would persistently prevent nicotine from reaching its receptors in the brain. To test this hypothesis, we constructed an AAVrh.10 vector that expressed a full-length, high-affinity, anti-nicotine antibody derived from the Fab fragment of the anti-nicotine monoclonal antibody NIC9D9 (AAVantiNic). In mice treated with this vector, blood concentrations of the antinicotine antibody were dose-dependent, and the antibody showed high specificity and affinity for nicotine. The antibody shielded the brain from systemically administered nicotine, reducing brain nicotine concentrations to 15% of those in naïve mice. The amount of nicotine sequestered in the serum of vector-treated mice was more than seven times greater than that in untreated mice, with 83% of serum nicotine bound to immunoglobulin G. Treatment with the AAVantiNic vector blocked nicotine-mediated alterations in arterial blood pressure, heart rate, and locomotor activity. In summary, a single administration of a gene transfer vector expressing a high-affinity anti-nicotine monoclonal antibody elicited persistent (18 weeks), high titers of an anti-nicotine antibody that obviated the physiologic effects of nicotine. If this degree of efficacy translates to humans, AAVantiNic could be an effective preventative therapy for nicotine addiction.

Original languageEnglish
Article number140ra87
JournalScience Translational Medicine
Volume4
Issue number140
DOIs
Publication statusPublished - 27 Jun 2012
Externally publishedYes

Fingerprint

Dependovirus
Smoking Cessation
Nicotine
Anti-Idiotypic Antibodies
Gene Expression
Antibodies
Brain
Monoclonal Antibodies
Immunoglobulin Fab Fragments
Locomotion
Serum
Smoke
Tobacco Products

ASJC Scopus subject areas

  • Medicine(all)

Cite this

AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation. / Hicks, Martin J.; Rosenberg, Jonathan B.; De, Bishnu P.; Pagovich, Odelya E.; Young, Colin N.; Qiu, Jian Ping; Kaminsky, Stephen M.; Hackett, Neil R.; Worgall, Stefan; Janda, Kim D.; Davisson, Robin L.; Crystal, Ronald.

In: Science Translational Medicine, Vol. 4, No. 140, 140ra87, 27.06.2012.

Research output: Contribution to journalArticle

Hicks, MJ, Rosenberg, JB, De, BP, Pagovich, OE, Young, CN, Qiu, JP, Kaminsky, SM, Hackett, NR, Worgall, S, Janda, KD, Davisson, RL & Crystal, R 2012, 'AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation', Science Translational Medicine, vol. 4, no. 140, 140ra87. https://doi.org/10.1126/scitranslmed.3003611
Hicks, Martin J. ; Rosenberg, Jonathan B. ; De, Bishnu P. ; Pagovich, Odelya E. ; Young, Colin N. ; Qiu, Jian Ping ; Kaminsky, Stephen M. ; Hackett, Neil R. ; Worgall, Stefan ; Janda, Kim D. ; Davisson, Robin L. ; Crystal, Ronald. / AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation. In: Science Translational Medicine. 2012 ; Vol. 4, No. 140.
@article{764290e9a5a74e72a2b029c8a6c66566,
title = "AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation",
abstract = "Current strategies to help tobacco smokers quit have limited success as a result of the addictive properties of the nicotine in cigarette smoke. We hypothesized that a single administration of an adeno-associated virus (AAV) gene transfer vector expressing high levels of an anti-nicotine antibody would persistently prevent nicotine from reaching its receptors in the brain. To test this hypothesis, we constructed an AAVrh.10 vector that expressed a full-length, high-affinity, anti-nicotine antibody derived from the Fab fragment of the anti-nicotine monoclonal antibody NIC9D9 (AAVantiNic). In mice treated with this vector, blood concentrations of the antinicotine antibody were dose-dependent, and the antibody showed high specificity and affinity for nicotine. The antibody shielded the brain from systemically administered nicotine, reducing brain nicotine concentrations to 15{\%} of those in na{\"i}ve mice. The amount of nicotine sequestered in the serum of vector-treated mice was more than seven times greater than that in untreated mice, with 83{\%} of serum nicotine bound to immunoglobulin G. Treatment with the AAVantiNic vector blocked nicotine-mediated alterations in arterial blood pressure, heart rate, and locomotor activity. In summary, a single administration of a gene transfer vector expressing a high-affinity anti-nicotine monoclonal antibody elicited persistent (18 weeks), high titers of an anti-nicotine antibody that obviated the physiologic effects of nicotine. If this degree of efficacy translates to humans, AAVantiNic could be an effective preventative therapy for nicotine addiction.",
author = "Hicks, {Martin J.} and Rosenberg, {Jonathan B.} and De, {Bishnu P.} and Pagovich, {Odelya E.} and Young, {Colin N.} and Qiu, {Jian Ping} and Kaminsky, {Stephen M.} and Hackett, {Neil R.} and Stefan Worgall and Janda, {Kim D.} and Davisson, {Robin L.} and Ronald Crystal",
year = "2012",
month = "6",
day = "27",
doi = "10.1126/scitranslmed.3003611",
language = "English",
volume = "4",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "140",

}

TY - JOUR

T1 - AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation

AU - Hicks, Martin J.

AU - Rosenberg, Jonathan B.

AU - De, Bishnu P.

AU - Pagovich, Odelya E.

AU - Young, Colin N.

AU - Qiu, Jian Ping

AU - Kaminsky, Stephen M.

AU - Hackett, Neil R.

AU - Worgall, Stefan

AU - Janda, Kim D.

AU - Davisson, Robin L.

AU - Crystal, Ronald

PY - 2012/6/27

Y1 - 2012/6/27

N2 - Current strategies to help tobacco smokers quit have limited success as a result of the addictive properties of the nicotine in cigarette smoke. We hypothesized that a single administration of an adeno-associated virus (AAV) gene transfer vector expressing high levels of an anti-nicotine antibody would persistently prevent nicotine from reaching its receptors in the brain. To test this hypothesis, we constructed an AAVrh.10 vector that expressed a full-length, high-affinity, anti-nicotine antibody derived from the Fab fragment of the anti-nicotine monoclonal antibody NIC9D9 (AAVantiNic). In mice treated with this vector, blood concentrations of the antinicotine antibody were dose-dependent, and the antibody showed high specificity and affinity for nicotine. The antibody shielded the brain from systemically administered nicotine, reducing brain nicotine concentrations to 15% of those in naïve mice. The amount of nicotine sequestered in the serum of vector-treated mice was more than seven times greater than that in untreated mice, with 83% of serum nicotine bound to immunoglobulin G. Treatment with the AAVantiNic vector blocked nicotine-mediated alterations in arterial blood pressure, heart rate, and locomotor activity. In summary, a single administration of a gene transfer vector expressing a high-affinity anti-nicotine monoclonal antibody elicited persistent (18 weeks), high titers of an anti-nicotine antibody that obviated the physiologic effects of nicotine. If this degree of efficacy translates to humans, AAVantiNic could be an effective preventative therapy for nicotine addiction.

AB - Current strategies to help tobacco smokers quit have limited success as a result of the addictive properties of the nicotine in cigarette smoke. We hypothesized that a single administration of an adeno-associated virus (AAV) gene transfer vector expressing high levels of an anti-nicotine antibody would persistently prevent nicotine from reaching its receptors in the brain. To test this hypothesis, we constructed an AAVrh.10 vector that expressed a full-length, high-affinity, anti-nicotine antibody derived from the Fab fragment of the anti-nicotine monoclonal antibody NIC9D9 (AAVantiNic). In mice treated with this vector, blood concentrations of the antinicotine antibody were dose-dependent, and the antibody showed high specificity and affinity for nicotine. The antibody shielded the brain from systemically administered nicotine, reducing brain nicotine concentrations to 15% of those in naïve mice. The amount of nicotine sequestered in the serum of vector-treated mice was more than seven times greater than that in untreated mice, with 83% of serum nicotine bound to immunoglobulin G. Treatment with the AAVantiNic vector blocked nicotine-mediated alterations in arterial blood pressure, heart rate, and locomotor activity. In summary, a single administration of a gene transfer vector expressing a high-affinity anti-nicotine monoclonal antibody elicited persistent (18 weeks), high titers of an anti-nicotine antibody that obviated the physiologic effects of nicotine. If this degree of efficacy translates to humans, AAVantiNic could be an effective preventative therapy for nicotine addiction.

UR - http://www.scopus.com/inward/record.url?scp=84863186975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863186975&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3003611

DO - 10.1126/scitranslmed.3003611

M3 - Article

VL - 4

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 140

M1 - 140ra87

ER -